Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
Open Access
- 1 March 2011
- journal article
- research article
- Published by Elsevier BV in Journal of Lipid Research
- Vol. 52 (3), 558-565
- https://doi.org/10.1194/jlr.m011080
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- A new method for measurement of total plasma PCSK9: clinical applicationsJournal of Lipid Research, 2010
- Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemiaJournal of Lipid Research, 2009
- PCSK9 as a therapeutic target of dyslipidemiaEmerging Therapeutic Targets, 2008
- Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy menClinical Endocrinology, 2007
- The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLRTraffic, 2007
- Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the ratJournal of Gastroenterology and Hepatology, 2004
- Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol AbsorptionScience, 2004
- Sterol Regulatory Element-binding Protein-2 Interacts with Hepatocyte Nuclear Factor-4 to Enhance Sterol Isomerase Gene Expression in HepatocytesOnline Journal of Public Health Informatics, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences of the United States of America, 2003
- Feedback and Hormonal Regulation of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase: The Concept of Cholesterol Buffering CapacityProceedings of the Society for Experimental Biology and Medicine, 2000